PARION SCIENCES, INC.

Company Information

Company Name
PARION SCIENCES, INC.
Address
2525 MERIDIAN PKY, STE 260
DURHAM, NC, 27713-2261
Phone
n/a
URL
n/a
DUNS
96851774
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,577,573.00
5
SBIR Phase II
$3,931,986.00
4
Chart code to be here

Award List

  1. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $159,264.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $489,999.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disorder characterized by lymphocyte-mediated destruction ofOverall, this application was found to hav ...

    SBIR Phase I 2005 Department of Health and Human Services
  3. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $364,501.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIR Phase I 2005 Department of Health and Human Services
  4. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $983,544.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIR Phase II 2006 Department of Health and Human Services
  5. PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $379,296.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involv ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. Hypertonic Saline for Cystic Fibrosis

    Amount: $244,797.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $1,059,726.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Novel Mucolytic Agents

    Amount: $319,012.00

    DESCRIPTION (provided by applicant): Mucus transport is the fundamental defense of the airways against inhaled particulates/infectious agents. Abnormalities in the mucus transport system characterize ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. Hypertonic Saline for Cystic Fibrosis

    Amount: $1,509,420.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIR Phase II 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government